Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

TransCode Therapeutics Yönetim

Yönetim kriter kontrolleri 4/4

TransCode Therapeutics' CEO'su Tom Fitzgerald, Jul2018 tarihinde atandı, in görev süresi 6.25 yıldır. in toplam yıllık tazminatı $ 426.86K olup, şirket hissesi ve opsiyonları dahil olmak üzere 83.9% maaş ve 16.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.008% ine doğrudan sahiptir ve bu hisseler $ 803.48 değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.3 yıl ve 6 yıldır.

Anahtar bilgiler

Tom Fitzgerald

İcra Kurulu Başkanı

US$426.9k

Toplam tazminat

CEO maaş yüzdesi	83.9%
CEO görev süresi	6.3yrs
CEO sahipliği	0.008%
Yönetim ortalama görev süresi	6.3yrs
Yönetim Kurulu ortalama görev süresi	6yrs

Son yönetim güncellemeleri

Recent updates

TransCode Therapeutics reports Q2 results

Aug 15

TransCode files U.S. patent application for radiotherapy based cancer treatment

Jul 11

We're Hopeful That TransCode Therapeutics (NASDAQ:RNAZ) Will Use Its Cash Wisely

Apr 01

Here's Why We're Not Too Worried About TransCode Therapeutics' (NASDAQ:RNAZ) Cash Burn Situation

Dec 15

CEO Tazminat Analizi

Tom Fitzgerald'un ücretlendirmesi TransCode Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$18m
Mar 31 2024	n/a	n/a	-US$17m
Dec 31 2023	US$427k	US$358k	-US$19m
Sep 30 2023	n/a	n/a	-US$20m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$19m
Dec 31 2022	US$561k	US$371k	-US$18m
Sep 30 2022	n/a	n/a	-US$15m
Jun 30 2022	n/a	n/a	-US$13m
Mar 31 2022	n/a	n/a	-US$6m
Dec 31 2021	US$318k	US$180k	-US$7m
Sep 30 2021	n/a	n/a	-US$5m
Jun 30 2021	n/a	n/a	-US$4m
Mar 31 2021	n/a	n/a	-US$7m
Dec 31 2020	US$15k	n/a	-US$2m

Tazminat ve Piyasa: Tom 'nin toplam tazminatı ($USD 426.86K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 677.23K ).

Tazminat ve Kazançlar: Tom 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Tom Fitzgerald (72 yo)

6.3yrs

Görev süresi

US$426,862

Tazminat

Mr. Thomas A. Fitzgerald, also known as Tom, M.B.A. has been the Director of TransCode Therapeutics Inc. since July 2018. He serves as Chief Financial Officer at TransCode Therapeutics, Inc. since July 201...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Philippe Calais	Executive Chairman of the Board	6yrs	US$112.61k	0.00093% $ 98.4
Thomas Fitzgerald	Interim CEO	6.3yrs	US$426.86k	0.0081% $ 862.6
Zdravka Medarova	Co-Founder & Chief Scientific Officer	8.8yrs	Veri yok	0% $ 0
Anna Moore	Co-Founder	8.8yrs	Veri yok	0% $ 0
Susan Duggan	Senior Vice President of Operations	no data	Veri yok	Veri yok
Daniel Vlock	Chief Medical Officer	less than a year	Veri yok	Veri yok

6.3yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim: RNAZ 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Philippe Calais	Executive Chairman of the Board	6yrs	US$112.61k	0.00093% $ 98.4
Thomas Fitzgerald	Interim CEO	6.3yrs	US$426.86k	0.0081% $ 862.6
Anna Moore	Co-Founder	8.8yrs	Veri yok	0% $ 0
John Henneman	Member of Advisory Board	no data	Veri yok	Veri yok
G. Srivatsa	Member of Advisory Board	no data	Veri yok	Veri yok
Magda Marquet	Independent Director	3.8yrs	US$75.11k	0% $ 0
Dmitry Samarsky	Member of Advisory Board	no data	Veri yok	Veri yok
Keith Flaherty	Member of Advisory Board	no data	Veri yok	Veri yok
Raul Mostoslavsky	Member of Advisory Board	no data	Veri yok	Veri yok
George Calin	Member of Advisory Board	no data	Veri yok	Veri yok
Raghu Kalluri	Member of Advisory Board	no data	Veri yok	Veri yok
Erik Manting	Independent Director	3.8yrs	US$73.11k	0% $ 0

6.0yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: RNAZ 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6 yıldır).

TransCode Therapeutics Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

TransCode Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

TransCode Therapeutics, Inc. Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

TransCode Therapeutics, Inc. Announces CEO Changes

TransCode Therapeutics, Inc. Announces CEO Changes

TransCode Therapeutics, Inc. Appoints Frank J. Slack to its Advisory Board

Co-Founder recently bought US$55k worth of stock

Recent updates

TransCode Therapeutics, Inc. Receives Non-Compliance Letter from Staff of Nasdaq

TransCode Therapeutics, Inc. Announces First Patients Treated in Phase 1 Clinical Trial with First-In-Class Lead Therapeutic Candidate

TransCode Therapeutics Receives Deficiency Letters from the Listing Qualifications Department (The “Staff”) of the Nasdaq

TransCode Therapeutics, Inc. Announces Phase 1 Clinical Trial Initiation

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $3 million.

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering.

TransCode Therapeutics, Inc. Reports Positive Data from First-In-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

TransCode Therapeutics Intends to File a Request for a Hearing on or before May 14, 2024, in Response to Non-Compliance with the Nasdaq Listing Rule 5550(a)(2)

TransCode Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

TransCode Therapeutics, Inc. Announces Fda Clearance to Initiate Phase 1/2 Clinical Trial Withttx-Mc138 in Patients with Advanced Solid Tumors

TransCode Therapeutics, Inc. Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.194863 million.

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.25 million.

TransCode Therapeutics, Inc. Announces CEO Changes

TransCode Therapeutics, Inc. Announces CEO Changes

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering.

TransCode Therapeutics, Inc. Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with Its Lead Candidate, TTX-MC138

TransCode Therapeutics, Inc. to Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $1.21 million.

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.21 million.

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.21 million.

TransCode Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Required for Continued Listing on The Nasdaq Capital Market

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on the Nasdaq Stock Market Subject to Conditions

Transcode Therapeutics, Inc. Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Leading Therapeutic Candidate, Tx-Mc138

TransCode Therapeutics, Inc. Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate,TTX-MC138

TransCode Therapeutics, Inc. Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial

TransCode Therapeutics Provides Non Compliance Update

TransCode Therapeutics Receives Delisting Determination Letter from Nasdaq Advising Not to Accept its Compliance Plan, and Denies its Request for an Extension

TransCode Therapeutics, Inc. Announces Publication of New Data Supporting Use of TTX-MC138 for Treatment of Metastatic Breast Cancer

New major risk - Shareholder dilution

TransCode Therapeutics, Inc. Reports Positive Preclinical Results with its Lead Candidate, Tx-MC138, in Glioblastoma

TransCode Therapeutics Announces 1-For-20 Reverse Stock Split to Satisfy the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

TransCode Therapeutics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement

TransCode Therapeutics, Inc. Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma

Transcode Therapeutics, Inc. Announces FDA Authorization to Proceed with First-In-Human Clinical Trial

Transcode Therapeutics Announces Eind Submission to Us Fda for Planned First-In-Human Clinical Trial in Patients with Advanced Solid Tumors

TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma

TransCode Therapeutics, Inc. Reports Positive Preclinical Results with Its Lead Candidate, TTX-MC138

TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology

TransCode Therapeutics, Inc. Appoints Frank J. Slack to its Advisory Board

TransCode Therapeutics reports Q2 results

TransCode files U.S. patent application for radiotherapy based cancer treatment

Co-Founder recently bought US$55k worth of stock

TransCode Therapeutics, Inc. Acquires Option for Radiotheranostic Technology

TransCode Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

We're Hopeful That TransCode Therapeutics (NASDAQ:RNAZ) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About TransCode Therapeutics' (NASDAQ:RNAZ) Cash Burn Situation

TransCode Therapeutics, Inc. Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Metastatic Breast Cancer

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş